CLAIM LISTING

1. (Previously presented) A compound of formula (Ia)



(Ia)

wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, nitro, cyano, formyl, or C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, C_{1-12}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-12}-alkyl, amino, acylamino, C_{1-12}-alkylamino, arylamino, aralkylamino, aminoC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12}-alkoxyC_{1-12}-alkyl, aryloxyC_{1-12}-alkyl, aralkoxyC_{1-12}-alkyl, C_{1-12}-alkylthio, thioC_{1-12}-alkyl, C_{1-12}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR^{11}, or -SO_2R^{12}, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, halogen, perhalomethyl, C_{1-6}-alkoxy or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;
or R^1 and R^2, R^2 and R^3 and/or R^3 and R^4 may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C_{1-6}-alkyl;

ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy or C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy or aryl;

X is a -(CHR^9)-CH_2-, -CH=CH-, -(NR^9)-CH_2-, -(CHR^9)-CH=CH-, -(CHR^9)-CH_2-CH_2-, -CH=(CR^9)-, -(CO)-(CHR^9)-, wherein R^9 is hydrogen, halogen, hydroxy, nitro, cyano, formyl, C_{1-12}-alkyl, C_{1-12}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, C_{1-12}-alkylamino, arylamino, aralkylamino, aminoC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, C_{1-12}-alkoxyC_{1-12}-alkyl, aryloxyC_{1-12}-alkyl, aralkoxyC_{1-12}-alkyl, C_{1-12}-alkylthio, thioC_{1-12}-alkyl, C_{1-12}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, -COR^{13}, or -SO_2R^{14}, wherein R^{13} and R^{14} independently of each other are selected from hydroxy, halogen, C_{1-6}-alkoxy, amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl;

Ar represents arylene or heteroarylene, optionally substituted with one or more C_{1-6}-alkyl or aryl;

R^5 represents hydrogen, hydroxy, halogen, C_{1-12}-alkoxy, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^5 forms a bond together with R^6,

R^6 represents hydrogen, hydroxy, halogen, C_{1-12}-alkoxy, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, acyl or aralkyl; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano; or R^6 forms a bond together with R^5,

R^7 represents hydrogen, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, aryl, aralkyl, C_{1-12}-alkoxyC_{1-12}-alkyl, C_{1-12}-alkoxycarbonyl, aryloxycarbonyl, C_{1-12}-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

R^8 represents hydrogen, C_{1-12}-alkyl, C_{4-12}-alkenynyl, C_{2-12}-alkenyl, C_{2-12}-alkynyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; optionally substituted with one or more halogen, perhalomethyl, hydroxy, nitro or cyano;

Y represents oxygen, sulphur or NR^{10}, where R^{10} represents hydrogen, C_{1-12}-alkyl, aryl, hydroxyC_{1-12}-alkyl or aralkyl groups or when Y is NR^{10}, R^8 and R^{10} may form a 5 or 6 membered nitrogen containing ring, optionally substituted with one or more C_{1-6}-alkyl;

n is an integer ranging from 1 to 4 and m is an integer ranging from 0 to 1;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein R^1, R^2, R^3, and R^4 independently of each other represent hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-7}-alkyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl, C_{1-7}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, $-COR^{11}$, or $-SO_2R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, perhalomethyl or amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano; or R^1 and R^2, R^2 and R^3 and/or R^3 and R^4 may form a cyclic ring containing from 5 to 7 carbon atoms optionally substituted with one or more C_{1-6}-alkyl.

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Previously presented) A compound according to claim 1 wherein ring A fused to the ring containing X and N represents a 5-6 membered cyclic ring, optionally substituted with one or more hydrogen, halogen, perhalomethyl, hydroxy, cyano, or C_{1-7}-alkyl, C_{4-7}-alkenynyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, C_{1-7}-alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyC_{1-7}-alkyl, amino, acylamino, C_{1-7}-alkylamino, arylamino, aralkylamino, aminoC_{1-7}-alkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, aryloxyC_{1-7}-alkyl, aralkoxyC_{1-7}-alkyl, C_{1-7}-alkylthio, thioC_{1-7}-alkyl, C_{1-7}-alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, $-COR^{11}$, or $-SO_2R^{12}$, wherein R^{11} and R^{12} independently of each other are selected from hydroxy, perhalomethyl or

amino optionally substituted with one or more C_{1-6}-alkyl, perhalomethyl or aryl; optionally substituted with one or more halogen, perhalomethyl, hydroxy or cyano.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

17. (Previously presented) A compound according to claim 1 wherein Ar represents arylene or heteroarylene;

R^5 represents hydrogen, hydroxy, halogen; or R^5 forms a bond together with R^6,

R^6 represents hydrogen, hydroxy, halogen; or R^6 forms a bond together with R^5,

R^7 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl, aryl, aralkyl, C_{1-7}-alkoxyC_{1-7}-alkyl, C_{1-7}-alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

R^8 represents hydrogen, C_{1-7}-alkyl, C_{2-7}-alkenyl, C_{2-7}-alkynyl;

Y represents oxygen or sulphur;

n is an integer ranging from 2 to 3 and m is 1.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)

31. (Cancelled)

32. (Cancelled)

33. (Cancelled)

34. (Cancelled)

35. (Cancelled)

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Cancelled)

40. (Cancelled)

41. (Cancelled)

42. (Cancelled)

43. (Cancelled)

44. (Cancelled)

45. (Previously presented) The compound according to claim 1 which is
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,
Ethyl-3-{4-[2-(10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionionate,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-methoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-propoxy-propionic acid,
3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-benzyloxy-propionic acid,
3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-2-methoxy-propionic acid,

3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-ethoxy-propionic acid,

3-{4-[3-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-2-methoxy-propionic acid,

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-2-ethoxy-propionic acid,

2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Propoxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Propoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[1-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-methoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Methoxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

2-Benzyloxy-3-{4-[3-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-propyl]-phenyl}-propionic acid,

3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionic acid,

Ethyl-3-(4-(2-(dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionionate,

3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-methoxy-propionic acid,

3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-propoxy-propionic acid,

3-(4-(2-(Dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-benzyloxy-propionic acid,

3-(4-(1-(Dibenzo[*b,f*]azepin-5-yl)-methoxy)-phenyl)-2-ethoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-ethoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-propoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propoxy)-phenyl)-2-benzyloxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-ethoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-propoxy-propionic acid,

3-(4-(3-(Dibenzo[*b,f*]azepin-5-yl)-propyl)-phenyl)-2-benzyloxy-propionic acid,

or a pharmaceutically acceptable salt thereof.

46. (Previously presented) The compound according to claim 1 which is

3-{4-[2-(10,11-Dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-2-ethoxy-propionic acid,

Ethyl-3-(4-(2-(10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy)-phenyl)-2-ethoxy-propionionate,

2-Ethoxy-3-{4-[2-(10-oxo-10,11-dihydro-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

2-Ethoxy-3-{4-[2-(10-methoxy-dibenzo[*b,f*]azepin-5-yl)-ethoxy]-phenyl}-propionic acid,

or a pharmaceutically acceptable salt thereof.

47. (Previously presented) A pharmaceutical composition comprising, as an active ingredient, a compound according to claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.

48. (Cancelled)

49. (Cancelled)

52. (Cancelled)

51. (Cancelled)

52. (Cancelled)

53. (Cancelled)

54. (Currently amended) A method for the treatment of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), **wherein the condition is selected from the following: type 2 diabetes, impaired glucose tolerance, hypertension, obesity, insulin resistance, hyperglycemia, atherosclerosis, hyperlipidemia, coronary artery disease, glomerulonephritis, glomerulosclerosis, nephritic syndrome, hypertensive nephrosclerosis, dementia, diabetic complications, psoriasis, polycystic ovarian syndrome and osteoporosis,** the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

55. (Previously presented) A method for the treatment of diabetes or obesity, the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

56. (Cancelled)

57. (Cancelled)

58. (Cancelled)

59. (Cancelled)

60. (Cancelled)